

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release



Notice Regarding Termination of Procedures Based on the Response Policy to Large-scale Purchase of Company Share Certificates etc., Following the Withdrawal of the Statement of Intent by Dalton etc.

TOKYO, September 30, 2025 - As ASKA Pharmaceutical Holdings Co., Ltd. (TSE: 4886, Head Office: Minato-ku, Tokyo / President, Representative Director: Sohta Yamaguchi; the "Company") introduced the "Response Policy to Large-scale Purchase etc. of Company Share Certificates etc. in Preparation for Large-scale Purchase etc. of Company Share Certificates etc. by Dalton etc." ("Response Policy") on July 1, 2025. Subsequently, on August 18, 2025, the Company received a statement of intent for large-scale purchase actions etc. ("Statement of Intent") from Dalton Investments, Inc. , Nippon Active Value Fund PLC, and NAVF Select LLC (collectively, "Dalton etc."), and commenced procedures ("Procedures") based on the Response Policy, including initiating the Board of Directors' Evaluation Period and sending the Information List to request information disclosure from Dalton etc.

However, today, the Company received a letter from Dalton etc., dated the same day, stating the withdrawal of the Statement of Intent ("Letter"). We hereby notify that, as a result of the Letter, the Large-scale Purchase etc. described in the Statement of Intent have been withdrawn, and accordingly, the Procedures have been terminated (consequently, the Board of Directors' Evaluation Period will be discontinued, the Information List for Dalton etc. will be withdrawn, and Dalton etc. will no longer be required to disclose information).

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp